Allogene Therapeutics (ALLO) Total Liabilities (2018 - 2026)

Allogene Therapeutics has reported Total Liabilities for 9 years, with the latest figure at $117.1 million in Q1 2026.

• Quarterly Total Liabilities fell 4.49% year-over-year to $117.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117.1 million (down 4.49% YoY) and the FY2025 annual result came in at $123.4 million, down 2.5% from the prior year.
• Total Liabilities slipped to $117.1 million in Q1 2026 per ALLO's latest filing, from $123.4 million in the prior quarter.
• Over five years, Total Liabilities peaked at $158.1 million in Q1 2023 and troughed at $112.8 million in Q1 2022.
• A 5-year average of $133.1 million and a median of $126.5 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities soared 44.92% in 2022, then fell 20.96% in 2024.
• Over 5 years, Total Liabilities stood at $154.7 million in 2022, then slipped by 15.57% to $130.6 million in 2023, then retreated by 3.12% to $126.5 million in 2024, then decreased by 2.5% to $123.4 million in 2025, then dropped by 5.09% to $117.1 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $117.1 million, $123.4 million, and $124.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.